免疫检查点抑制剂治疗期间肺磨玻璃结节短期CT定量变化
本研究回顾性比较接受免疫检查点抑制剂治疗的恶性肿瘤患者肺磨玻璃结节与未治疗对照结节的短期CT变化。匹配分析显示,ICI组结节直径下降,对照组直径和体积增加。ICI组直径和体积的月变化率均低于对照组,但结果应视为关联而非因果效应。
要点
- ICI治疗期间磨玻璃结节直径可出现下降,需与稳定性或自然消退相鉴别
- 随访中应同时监测直径、体积和实性成分比例的变化
- ICI组结节体积进展的几率低于对照组,但不能据此判断为治疗获益
核心结论
- ICI治疗组磨玻璃结节短期定量CT轨迹与未治疗组不同,表现为更低的直径和体积月增长率。
- ICI组与较低的体积变化率及较低的体积进展几率相关,但研究仅提示关联,不能推断因果关系。
研究设计与样本
- 回顾性探索性队列研究,ICI队列从1930例恶性肿瘤合并肺结节患者中筛选,最终纳入98例,每例选取一个目标磨玻璃结节。
- 80例进入患者水平匹配分析,匹配对照组来自健康筛查CT偶然发现磨玻璃结节的人群,共纳入80例匹配对照。
- 基线和随访CT评估直径、体积、CT衰减值和实性成分比例变化,并以月变化率和多变量分析评价体积变化与进展。
关键影像表现/征象
- 匹配队列中,ICI组磨玻璃结节直径下降,对照组磨玻璃结节直径和体积均增加。
- ICI组直径月变化率低于对照组,ICI组体积月变化率亦低于对照组。
诊断标准与关键数值
- ICI组与对照组直径月变化率分别为-0.062 mm/月和0.048 mm/月,FDR小于0.001。
- ICI组与对照组体积月变化率分别为-0.855 mm3/月和2.425 mm3/月,FDR等于0.001。
- 多变量分析中,ICI组与更低的体积变化率相关,β为-11.28,95%置信区间-22.34至-0.23,P等于0.046。
- ICI组发生体积进展的比值比为0.43,95%置信区间0.19至0.93,P等于0.037。
临床应用与阅片要点
- 阅片随访时对接受ICI治疗的肿瘤患者肺内磨玻璃结节,应记录直径、体积和实性成分比例,并使用与基线一致的测量方法。
- ICI治疗期间磨玻璃结节短期缩小不等于良性或治疗有效,应结合整体肿瘤反应和免疫相关影像表现判断。
- 随访间隔和结节管理决策不应仅基于短期CT轨迹,需考虑患者原发肿瘤状态和免疫治疗相关风险。
局限性
- 回顾性探索性研究设计,样本量较小,匹配分析仅纳入80例患者和80例对照。
- 观察性研究仅能报告关联,无法得出ICI治疗对磨玻璃结节因果效应的结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The short-term CT behavior of pulmonary ground-glass nodules (GGNs) during immune checkpoint inhibitor (ICI) therapy remains uncertain. We compared longitudinal CT changes in GGNs observed during ICI therapy with those in a matched surveillance cohort of untreated GGNs.
METHODS: In this retrospective exploratory study, the ICI cohort was identified from 1,930 patients with malignant tumors and synchronous pulmonary nodules. After eligibility screening, 98 patients with one target GGN per patient were included, and 80 patients entered the patient-level matched analysis. The comparator cohort was derived from individuals with incidentally detected GGNs on health screening CT, and 80 matched controls were included. Baseline and follow-up CT scans were assessed for changes in diameter, volume, CT attenuation, and solid component proportion. Monthly change rates and multivariable analyses were used to evaluate volume change and progression.
RESULTS: In the matched cohort, GGNs in the ICI group showed a decrease in diameter, whereas control GGNs showed increases in both diameter and volume. Compared with controls, the ICI group had lower monthly rates of change in diameter (-0.062 vs 0.048 mm/month; FDR < 0.001) and volume (-0.855 vs 2.425 mm3/month; FDR = 0.001). In multivariable analysis, ICI-group assignment remained associated with a lower Δvolume rate (β = -11.28, 95% CI -22.34 to -0.23; p = 0.046) and lower odds of volumetric progression (OR = 0.43, 95% CI 0.19-0.93; p = 0.037).
CONCLUSIONS: ICI-treated GGNs showed different short-term quantitative CT trajectories compared with untreated ones, particularly lower monthly growth in diameter and volume. However, these observational findings should be interpreted as associations rather than causal treatment effects.
引用
- Luo, Zheng, Li, et al. Short-term quantitative CT trajectories of pulmonary Ground-Glass nodules during immune checkpoint inhibitor Therapy: A matched surveillance cohort study. Eur J Radiol. 2026. PMID: 42456619. doi:10.1016/j.ejrad.2026.113069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。